BTMD Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 20.83% compared to Biote's net margin of 3.36%. Biote's return on equity of -- beat Astrana Health's return on equity of 12.67%.

Biote has a consensus price target of --, signalling upside risk potential of 62.79%. On the other hand Astrana Health has an analysts' consensus of $64.5000 which suggests that it could grow by 91.4%. Given that Astrana Health has higher upside potential than Biote, analysts believe Astrana Health is more attractive than Biote.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.363%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 262.18% of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Biote quarterly revenues are $51.4M, which are smaller than Astrana Health quarterly revenues of $478.7M. Biote's net income of $10.7M is lower than Astrana Health's net income of $16.1M. Notably, Biote's price-to-earnings ratio is 23.50x while Astrana Health's PE ratio is 25.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 1.06x versus 0.93x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 20.83% compared to Biote's net margin of 8.15%. Biote's return on equity of -- beat Cryo-Cell International's return on equity of --.

Biote has a consensus price target of --, signalling upside risk potential of 62.79%. On the other hand Cryo-Cell International has an analysts' consensus of $9.00 which suggests that it could grow by 14.94%. Given that Biote has higher upside potential than Cryo-Cell International, analysts believe Biote is more attractive than Cryo-Cell International.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.887%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.19% to investors and pays a quarterly dividend of $0.25 per share. Biote pays 262.18% of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.

Biote quarterly revenues are $51.4M, which are larger than Cryo-Cell International quarterly revenues of $8M. Biote's net income of $10.7M is higher than Cryo-Cell International's net income of $655.8K. Notably, Biote's price-to-earnings ratio is 23.50x while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 1.06x versus 2.03x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of 20.83% compared to Biote's net margin of 3.06%. Biote's return on equity of -- beat Omnicell's return on equity of -1.47%.

Biote has a consensus price target of --, signalling upside risk potential of 62.79%. On the other hand Omnicell has an analysts' consensus of -- which suggests that it could grow by 25.77%. Given that Biote has higher upside potential than Omnicell, analysts believe Biote is more attractive than Omnicell.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.577%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 262.18% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Biote quarterly revenues are $51.4M, which are smaller than Omnicell quarterly revenues of $282.4M. Biote's net income of $10.7M is higher than Omnicell's net income of $8.6M. Notably, Biote's price-to-earnings ratio is 23.50x while Omnicell's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 1.06x versus 1.94x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 20.83% compared to Biote's net margin of -12.84%. Biote's return on equity of -- beat P3 Health Partners's return on equity of -26.35%.

Biote has a consensus price target of --, signalling upside risk potential of 62.79%. On the other hand P3 Health Partners has an analysts' consensus of -- which suggests that it could grow by 228.95%. Given that P3 Health Partners has higher upside potential than Biote, analysts believe P3 Health Partners is more attractive than Biote.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 262.18% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Biote quarterly revenues are $51.4M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. Biote's net income of $10.7M is higher than P3 Health Partners's net income of -$46.5M. Notably, Biote's price-to-earnings ratio is 23.50x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 1.06x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.